

Prior Authorization Request Form for ozanimod (Zeposia)



JOHNS HOPKINS
MEDICINE

JOHNS HOPKINS
HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

**FAX Completed Form and
Applicable Progress Notes to:
(410) 424-4037**

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step 1 Please complete patient and physician information (please print):

<p>1 Patient Name: _____ Physician Name: _____</p> <p>Address: _____ Address: _____</p> <p>Sponsor ID # _____ Phone #: _____</p> <p>Date of Birth: _____ Secure Fax #: _____</p>	
---	--

Step 2 Please complete the clinical assessment:

<p>2 1. Is the requested medication prescribed by a neurologist?</p>	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No STOP Coverage not approved
<p>2. Does the patient have a documented diagnosis of relapsing forms of multiple sclerosis (MS)?</p>	<input type="checkbox"/> Yes Proceed to question 3	<input type="checkbox"/> No STOP Coverage not approved
<p>3. Is the patient concurrently using a disease-modifying therapy (for example, beta interferons [Avonex, Betaseron, Rebif, Plegridy, Extavia], glatiramer [Copaxone, Glatopa], dimethyl fumarate [Tecfidera], diroximel fumarate [Vumerity], monomethyl fumarate [Bafiertam], cladribine [Mavenclad], teriflunamide [Aubagio])?</p>	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 4
<p>4. Has the patient previously failed a treatment course of fingolimod (Gilenya)?</p>	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 5
<p>5. Has the patient previously failed a treatment course of siponimod (Mayzent)?</p>	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 6
<p>6. Does the provider acknowledge that all recommended Zeposia monitoring has been completed and the patient will be monitored throughout treatment as recommended in the label? Monitoring includes the following:</p> <ul style="list-style-type: none"> • complete blood count (CBC), • liver function tests (LFT), • varicella zoster virus (VZV) antibody serology, • electrocardiogram (ECG), and • macular edema screening as indicated 	<input type="checkbox"/> Yes Proceed to question 7	<input type="checkbox"/> No STOP Coverage not approved

Prior Authorization Request Form for ozanimod (Zeposia)

<p>7. Will the requested medication be used in patients with significant cardiac history, including:</p> <ul style="list-style-type: none"> • Patients with a recent history (within the past 6 months) of class III/IV heart failure, myocardial infarction, unstable angina, stroke, transient ischemic attack, or decompensated heart failure requiring hospitalization • Patients with a history or presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block or sick sinus syndrome, unless they have a functioning pacemaker? 	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Sign and date below
---	--	---

Step 3 I certify the above is true to the best of my knowledge.

Please sign and date:

_____ Prescriber Signature

_____ Date

[11 November 2020]

For Internal Use Only	
<input type="checkbox"/> Approved:	Duration of Approval: _____month(s)
<input type="checkbox"/> Denied:	Authorized By:
<input type="checkbox"/> Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: